🇺🇸 pegaptanib sodium injection in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Aortic Arteriosclerosis — 1 report (12.5%)
2. Condition Aggravated — 1 report (12.5%)
3. Fall — 1 report (12.5%)
4. Hip Fracture — 1 report (12.5%)
5. Lumbar Spinal Stenosis — 1 report (12.5%)
6. Nephrolithiasis — 1 report (12.5%)
7. Vitrectomy — 1 report (12.5%)
8. Vitreous Haemorrhage — 1 report (12.5%)

Source database →

Frequently asked questions

Is pegaptanib sodium injection approved in United States?

pegaptanib sodium injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for pegaptanib sodium injection in United States?

Bausch & Lomb Incorporated is the originator. The local marketing authorisation holder may differ — check the official source linked above.